publication date: Feb. 14, 2020

Ohio State expands assistance program to give out previously dispensed cancer drugs

By Alexandria Carolan

A program at Ohio State is trying to make use of cancer drugs that would otherwise go to waste.

Through a pilot program, the institution’s drug repository is accepting oral drugs originally prescribed to patients who no longer need them and distributing these drugs to patients who are at risk of financial toxicity.

The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has expanded its drug repository program to include previously-dispensed oral cancer medications associated with high co-pays and costs—Xeloda (capecitabine) and Temodar (temozolomide).

The program became feasible last October, after the State of Ohio Board of Pharmacy amended its long-standing rule and allowed patients to donate oral cancer medications directly to drug repository programs in Ohio.

Before the rule change, only unopened medications that were not in the possession of patients could be donated to drug repository programs. Now, drugs that would ordinarily sit in medicine cabinets or would be disposed of can be accepted by the repository.

“Our goal is to have proof of concept to establish best practices and make sure that we have a very efficient process for receiving and re-dispensing—and then to scale this program to include all oral chemotherapy medications,” Julie Kennerly-Shah, a pharmacist and associate director of pharmacy at the OSUCCC–James, said to The Cancer Letter. “Because there’s certainly a need outside of these initial two medications.”

The drugs are now available through the overall Medical Assistance Program at OSUCCC–James.

Drug repository programs in other states—Wyoming, Florida, Nevada, Iowa and Wisconsin— informed the updated … Continue reading Ohio State expands assistance program to give out previously dispensed cancer drugs

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.